Abstract
Twenty cases of interstitial pneumonia secondary to treatment with granulocyte colony-stimulating factor (G-CSF) were reviewed. Their interstitial pneumonia had the following features: (a) it occurred predominantly in patients aged 60 years or older; (b) it was prevalent among patients with haematological malignancies, particularly non-Hodgkin's lymphoma; (c) in all patients G-CSF was given after anti-cancer agents with potential to affect the lungs; (d) at the onset, many patients had symptoms such as dyspnoea and fever, and (e) the leucocyte (neutrophil) count as well as lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels were usually higher than normal at the onset. These findings indicate that, when G-CSF is used in combination with pneumotoxic anti-cancer agents, respiratory function should be monitored before and during treatment. if the leucocyte (or neutrophil) count and/or LDH and CRP increase suddenly in association with dyspnoea and fever during administration of G-CSF, interstitial pneumonia should be suspected. Accordingly, a chest radiograph and pulmonary functional tests should be performed promptly. If a diagnosis of interstitial pneumonia is made, steroid pulse therapy should be commenced immediately.
Author supplied keywords
Cite
CITATION STYLE
Niitsu, N., Iki, S., Muroi, K., Motomura, S., Murakami, M., Takeyama, H., … Urabe, A. (1997). Interstitial pneumonia in patients receiving granulocyte colony stimulating factor during chemotherapy: Survey in Japan 1991-96. British Journal of Cancer, 76(12), 1661–1666. https://doi.org/10.1038/bjc.1997.614
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.